REGENXBIO Inc. Deferred Revenue, Revenue Recognized
REGENXBIO Inc. (RGNX) reported Deferred Revenue, Revenue Recognized of $3.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2026-08-06
- REGENXBIO Inc. deferred revenue, revenue recognized for the quarter ending 2026-06-30 was $3.41M, a 62.02% increase year-over-year.
- REGENXBIO Inc. deferred revenue, revenue recognized for the quarter ending 2026-03-31 was $700.00K, a 525.00% increase year-over-year.
- REGENXBIO Inc. deferred revenue, revenue recognized for the quarter ending 2025-09-30 was $3.40M, a 16095.24% increase year-over-year.
- REGENXBIO Inc. deferred revenue, revenue recognized for the quarter ending 2025-06-30 was $2.10M, a 16084.62% increase year-over-year.
- REGENXBIO Inc. deferred revenue, revenue recognized for fiscal 2025 was $115.00K, a 22.30% decline from fiscal 2024.
- REGENXBIO Inc. deferred revenue, revenue recognized for fiscal 2024 was $148.00K, a 91.33% decline from fiscal 2023.
- REGENXBIO Inc. deferred revenue, revenue recognized for fiscal 2023 was $1.71M, a 48.75% decline from fiscal 2022.
- REGENXBIO Inc. deferred revenue, revenue recognized for fiscal 2022 was $3.33M, a 754.62% increase from fiscal 2021.
| Period end | Deferred Revenue, Revenue Recognized 3 month | Deferred Revenue, Revenue Recognized 6 month | Deferred Revenue, Revenue Recognized 9 month | Deferred Revenue, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.41M 10-Q · filed 2026-08-06 | $4.11M 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $700.00K 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $115.00K 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $3.40M 10-Q · filed 2025-11-06 | $115.00K 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $2.10M 10-Q · filed 2026-08-06 | $115.00K 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $112.00K 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | $148.00K 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $21.00K 10-Q · filed 2025-11-06 | $148.00K 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $13.00K 10-Q · filed 2025-08-07 | $148.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $148.00K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $1.71M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $28.00K 10-Q · filed 2024-11-06 | $1.41M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $891.00K 10-Q · filed 2024-08-01 | $1.41M 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $930.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $3.33M 10-K · filed 2025-03-13 | |||
| 2022-09-30 | $1.34M 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $390.00K 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $99.00K 10-Q · filed 2022-11-03 | $306.00K 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $99.00K 10-Q · filed 2022-08-03 | $207.00K 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | $108.00K 10-Q · filed 2022-05-04 | |||
| 2020-09-30 | $113.00K 10-Q · filed 2021-11-02 | |||
| 2019-12-31 | $600.00K 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $600.00K 10-Q · filed 2020-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |